Niceritrol
Chemical compound
- C10AD01 (WHO)
- 3-[(pyridin-3-yl)carbonyloxy]-2,2-bis({[(pyridin-3-yl)carbonyloxy]methyl})propyl pyridine-3-carboxylate
- 5868-05-3
Y
- 4476
- 4321
N
- F54EHJ34MV
- D01754 Y
- DTXSID1023364
- Interactive image
- C1=CC(=CN=C1)C(=O)OCC(COC(=O)C2=CN=CC=C2)(COC(=O)C3=CN=CC=C3)COC(=O)C4=CN=CC=C4
InChI
- InChI=1S/C29H24N4O8/c34-25(21-5-1-9-30-13-21)38-17-29(18-39-26(35)22-6-2-10-31-14-22,19-40-27(36)23-7-3-11-32-15-23)20-41-28(37)24-8-4-12-33-16-24/h1-16H,17-20H2N
- Key:KUEUWHJGRZKESU-UHFFFAOYSA-NN
N
Y (what is this?) (verify)Niceritrol is a niacin derivative used as a hypolipidemic agent. It is an ester of pentaerythritol and nicotinic acid, has general properties similar to those of nicotinic acid (Nicotinamide), to which it is slowly hydrolysed. Niceritrol has been used as a lipid regulating drug in hyperlipidaemias and as a vasodilator in the treatment of peripheral vascular disease.[1][2]
References
- ^ Owada A, Suda S, Hata T (April 2003). "Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial". The American Journal of Medicine. 114 (5): 347–53. doi:10.1016/s0002-9343(02)01567-x. PMID 12714122.
- ^ Truven Health Analytics Inc. (May 8, 2008). "Niceritrol". Micromedexsolutions.com. Retrieved December 14, 2014.
- v
- t
- e
Lipid-lowering agents (C10)
| Cholesterol absorption inhibitors, NPC1L1 | |
|---|---|
| Bile acid sequestrants/resins (LDL) |
| Statins (HMG-CoA reductase, LDL) | |
|---|---|
| Niacin and derivatives (HDL and LDL) | |
| MTTP inhibitors (VLDL) | |
| ATP citrate lyase inhibitors (LDL) | |
| Thyromimetics (VLDL) |
| PPAR agonists (LDL) |
| ||||
|---|---|---|---|---|---|
| CETP inhibitors (HDL) | |||||
| PCSK9 inhibitors (LDL) | |||||
| ANGPTL3 inhibitors (LDL/HDL) |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
